Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway. 31289569 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE The binding of ALKBH5 and NEAT1 influences the expression of EZH2 (a subunit of the polycomb repressive complex) and thus affects GC invasion and metastasis. 31290116 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE EZH2 augmented p53 GOF mutant-mediated cancer growth and metastasis by increasing protein levels of mutant p53. 30723117 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE Furthermore, AGAP2-AS1 epigenetically inhibited the expression of ANKRD1 and ANGPTL4 by recruiting zeste homolog 2 (EZH2), thereby promoting PC proliferation and metastasis. 30814490 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE Long non-coding RNA ZNFX1-AS1 promotes the tumor progression and metastasis of colorectal cancer by acting as a competing endogenous RNA of miR-144 to regulate EZH2 expression. 30770796 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE Epithelial-mesenchymal transition (EMT) and the histone methyltransferase Enhancer of Zeste Homologue 2 (EZH2) are important regulators of lung cancer progression and metastasis. 31042721 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE Knockdown of MLK4 inhibited HCC cell proliferation and metastasis, which was partly through reducing matrix metalloproteinase (MMP)-13, MMP2, enhancer of zeste homolog 2 (EZH2) and Vimentin expressions. 31071576 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE EZH2-mediated epigenetic suppression of EphB3 inhibits gastric cancer proliferation and metastasis by affecting E-cadherin and vimentin expression. 30408551 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE Absence of HMGA2 or EZH2 expression or chemical inhibition of Wnt signaling in a chemoresistant patient-derived xenograft (PDX) model of TNBC abolished visceral metastasis, repressing AXIN2, MYC, EZH2, and HMGA2 expression i<i>n vivo</i>. 30563890 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE These results suggest a potential role of EZH2 for the PTC growth and metastasis. 31718595 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE Meanwhile, inhibited IGSF1 expression could downregulate N-cadherin, vimentin, and EZH2, which is associated with metastasis. 31343762 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE <b>Conclusions:</b> A cisplatin-HOXB13-ABCG1/EZH2/Slug network may account for a novel mechanism underlying cisplatin resistance and metastasis after chemotherapy. 31037158 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE Finally, the combination of si-EZH2 and inhibitor was used to further verify whether microRNA-130-5p could promote cell metastasis and invasion of lung cancer by targeting EZH2. 31773700 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE The results indicate that linc-UBC1 is a novel oncogene in tumorigenesis and could promote the metastasis via EZH2 and E-cadherin, which may offer a possible therapeutic target in ESCC. 29552776 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE The loss of PSP94 expression was inversely correlated to EZH2 expression (<i>P</i> < 0.0001) and largely unrelated to the ERG status, but strongly correlated with high Gleason grade, advanced tumor stage, and nodal metastasis ( <i>P</i> <0.0001 each). 31516752 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE No association was observed between normal adjacent prostate EZH2 expression and biochemical recurrence or metastasis. 31104332 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE In conclusion, we proposed that EZH2 regulates EMT and tumor invasion and metastasis in HNSCC by governing the STAT3/VEGFR2 axis. 31545422 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 PosttranslationalModification phenotype BEFREE EZH2-DNMT1-mediated epigenetic silencing of miR-142-3p promotes metastasis through targeting ZEB2 in nasopharyngeal carcinoma. 30353102 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE MALAT1 could affect EMT and metastasis of EC cells through Ezh2-Notch1 signaling pathway. 29916899 2018
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma. 29653269 2018
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 Biomarker phenotype BEFREE However, it is unclear whether this extranuclear, epigenetic-independent function of EZH2 has a profound impact on the initiation of cellular transformation and metastasis. 28967906 2018
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE Overall, the present study demonstrated that the lncRNA PVT1 may contribute to the tumorigenesis and metastasis of melanoma through binding to EZH2 and regulating the expression of miR‑200c. lncRNA PVT1 may serve as a potential target for the therapy of melanoma. 29286144 2018
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE Enhancer of Zeste homologue 2 (EZH2) overexpression is associated with tumor proliferation, metastasis, and poor prognosis. 30469511 2018
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE Conversely, UTX-1 depletion and ectopic expression of EZH2 enhanced EMT and tumor metastasis in DLD1 cells. 28513825 2018
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
0.100 AlteredExpression phenotype BEFREE A higher expression of RING1B and EZH2 was detected by immunohistochemistry in a series of primary cSCC tumors that metastasized (MSCCs) when compared with non-metastasizing cSCCs (non-MSCCs). 29394319 2018